Kruppel-like factors in muscle health and disease

Trends in Cardiovascular Medicine

Volumn 25, Issue 4, 2015, Pages 278-287

  Prosdocimo, Domenick A ^a,b,c   Sabeh, M Khaled ^a,b,c   Jain, Mukesh K ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harrington Heart and Vascular Institute   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR;

CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DNA BINDING; HEART DEVELOPMENT; HEART MUSCLE; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; KNOWLEDGE; MUSCLE; MUSCLE DEVELOPMENT; MUSCLE DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; VASCULAR SMOOTH MUSCLE; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; GENETICS; HOMEOSTASIS; METABOLISM; SMOOTH MUSCLE; UPREGULATION;

CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MUSCLE, SKELETAL; MUSCLE, SMOOTH; MYOCARDIUM; UP-REGULATION;

EID: 84928762309     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.11.006     Document Type: Review

References (80)

1. Turk-Adawi K., Sarrafzadegan N., Grace S.L. Global availability of cardiac rehabilitation. Nat Rev Cardiol 2014, 11:586-596.
2. McConnell B.B., Yang V.W. Mammalian Kruppel-like factors in health and diseases. Physiol Rev 2010, 90:1337-1381.
3. Nusslein-Volhard C., Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287:795-801.
4. Haldar S.M., Ibrahim O.A., Jain M.K. Kruppel-like Factors (KLFs) in muscle biology. J Mol Cell Cardiol 2007, 43:1-10.
5. van der Bom T., Zomer A.C., Zwinderman A.H., Meijboom F.J., Bouma B.J., Mulder B.J. The changing epidemiology of congenital heart disease. Nature reviews. Cardiology 2011, 8:50-60.
6. Andersen T.A., Troelsen Kde L., Larsen L.A. Of mice and men: molecular genetics of congenital heart disease. Cell Mol Life Sci 2014, 71:1327-1352.
7. McCulley D.J., Black B.L. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 2012, 100:253-277.
8. Lavallee G., Andelfinger G., Nadeau M., Lefebvre C., Nemer G., Horb M.E., et al. The Kruppel-like transcription factor KLF13 is a novel regulator of heart development. EMBO J 2006, 25:5201-5213.
9. Grepin C., Dagnino L., Robitaille L., Haberstroh L., Antakly T., Nemer M. A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol 1994, 14:3115-3129.
10. Kelsey L., Flenniken A.M., Qu D., Funnell A.P., Pearson R., Zhou Y.Q., et al. ENU-induced mutation in the DNA-binding domain of KLF3 reveals important roles for KLF3 in cardiovascular development and function in mice. PLoS Genet 2013, 9:e1003612.
11. van Berlo J.H., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Investig 2013, 123:37-45.
12. Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002, 8:856-863.
13. Nagai R., Shindo T., Manabe I., Suzuki T., Kurabayashi M. KLF5/BTEB2, a Kruppel-like zinc-finger type transcription factor, mediates both smooth muscle cell activation and cardiac hypertrophy. Adv Exp Med Biol 2003, 538:57-65. [discussion 6].
14. Takeda N., Manabe I., Uchino Y., Eguchi K., Matsumoto S., Nishimura S., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Investig 2010, 120:254-265.
15. Fisch S., Gray S., Heymans S., Haldar S.M., Wang B., Pfister O., et al. Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2007, 104:7074-7079.
16. Haldar S.M., Lu Y., Jeyaraj D., Kawanami D., Cui Y., Eapen S.J., et al. Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Transl Med 2010, 2:26ra.
17. Subramaniam M., Harris S.A., Oursler M.J., Rasmussen K., Riggs B.L., Spelsberg T.C. Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res 1995, 23:4907-4912.
18. Rajamannan N.M., Subramaniam M., Abraham T.P., Vasile V.C., Ackerman M.J., Monroe D.G., et al. TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: discovery and characterization of a novel signaling pathway. J Cell Biochem 2007, 100:315-325.
19. Leenders J.J., Pinto Y.M., Creemers E.E. Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling. J Mol Cell Cardiol 2011, 51:156-167.
20. Bos J.M., Subramaniam M., Hawse J.R., Christiaans I., Rajamannan N.M., Maleszewski J.J., et al. TGFbeta-inducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. J Cell Biochem 2012, 113:1896-1903.
21. Yoshida T., Gan Q., Franke A.S., Ho R., Zhang J., Chen Y.E., et al. Smooth and cardiac muscle-selective knock-out of Kruppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem 2010, 285:21175-21184.
22. Jain M.K., Sangwung P., Hamik A. Regulation of an inflammatory disease: Kruppel-like factors and atherosclerosis. Arterioscler Thromb Vasc Biol 2014, 34:499-508.
23. Liao X., Haldar S.M., Lu Y., Jeyaraj D., Paruchuri K., Nahori M., et al. Kruppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:334-338.
24. Yoshida T., Yamashita M., Horimai C., Hayashi M. Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity. J Biol Chem 2014, 289:26107-26118.
25. Goldberg I.J., Trent C.M., Schulze P.C. Lipid metabolism and toxicity in the heart. Cell Metab 2012, 15:805-812.
26. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258.
27. Kolwicz S.C., Tian R. Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?. Trends Cardiovasc Med 2009, 19:201-207.
28. Bertrand L., Horman S., Beauloye C., Vanoverschelde J.L. Insulin signalling in the heart. Cardiovasc Res 2008, 79:238-248.
29. Madrazo J.A., Kelly D.P. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008, 44:968-975.
30. Wright M.B., Bortolini M., Tadayyon M., Bopst M. Minireview: challenges and opportunities in development of PPAR agonists. Mol Endocrinoly 2014, 10.1210/me.2013-1427.
31. Prosdocimo D.A., Anand P., Liao X., Zhu H., Shelkay S., Artero-Calderon P., et al. Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem 2014, 289:5914-5924.
32. Campbell F.M., Kozak R., Wagner A., Altarejos J.Y., Dyck J.R., Belke D.D., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002, 277:4098-4103.
33. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
34. Knoedler J.R., Denver R.J. Kruppel-like factors are effectors of nuclear receptor signaling. Gen Comp Endocrinol 2014, 203:49-59.
35. Nair G.M., Nery P.B., Redpath C.J., Birnie D.H. Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction: a current perspective. Curr Opin Cardiol 2014, 29:152-159.
36. Goldenberg I., Moss A.J. Long QT syndrome. J Am Coll Cardiol 2008, 51:2291-2300.
37. Patel U., Pavri B.B. Short QT syndrome: a review. Cardiol Rev 2009, 17:300-303.
38. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. American journal of physiology. Heart Circ Physiol 2007, 293:H2024-H2038.
39. Muller J.E., Ludmer P.L., Willich S.N., Tofler G.H., Aylmer G., Klangos I., et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987, 75:131-138.
40. Bass J., Takahashi J.S. Circadian integration of metabolism and energetics. Science 2010, 330:1349-1354.
41. Reppert S.M., Weaver D.R. Coordination of circadian timing in mammals. Nature 2002, 935-941.
42. Jeyaraj D., Haldar S.M., Wan X., McCauley M.D., Ripperger J.A., Hu K., et al. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 2012, 483:96-99.
43. Shimizu W., Horie M. Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res 2011, 109:97-109.
44. Bonnet D., Martin D., Pascale De L., Villain E., Jouvet P., Rabier D., et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999, 100:2248-2253.
45. Saudubray J.M., Martin D., de Lonlay P., Touati G., Poggi-Travert F., Bonnet D., et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 1999, 22:488-502.
46. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 2010, 33:501-506.
47. Yamada K.A., Kanter E.M., Newatia A. Long-chain acylcarnitine induces Ca2+ efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol 2000, 36:14-21.
48. Xu Z. Rozanski GJ. K+ current inhibition by amphiphilic fatty acid metabolites in rat ventricular myocytes. Am J Physiol 1998, 275(6 Pt 1):C1660-C1667.
49. +]i and initiates transient inward current in adult ventricular myocytes. Am J Physiol 1995, 268(6 Pt 2):H2405-H2417.
50. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
51. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
52. Kuo C.T., Veselits M.L., Barton K.P., Lu M.M., Clendenin C., Leiden J.M. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev 1997, 11:2996-3006.
53. Wu J., Bohanan C.S., Neumann J.C., Lingrel J.B. KLF2 transcription factor modulates blood vessel maturation through smooth muscle cell migration. J Biol Chem 2008, 283:3942-3950.
54. Adam P.J., Regan C.P., Hautmann M.B., Owens G.K. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J Biol Chem 2000, 275:37798-37806.
55. Liu Y., Sinha S., McDonald O.G., Shang Y., Hoofnagle M.H., Owens G.K. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J Biol Chem 2005, 280:9719-9727.
56. Alaiti M.A., Orasanu G., Tugal D., Lu Y., Jain M.K. Kruppel-like factors and vascular inflammation: implications for atherosclerosis. Curr Atheroscler Rep 2012, 14:438-449.
57. Pidkovka N.A., Cherepanova O.A., Yoshida T., Alexander M.R., Deaton R.A., Thomas J.A., et al. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res 2007, 101:792-801.
58. Yoshida T., Kaestner K.H., Owens G.K. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res 2008, 102:1548-1557.
59. Salmon M., Johnston W.F., Woo A., Pope N.H., Su G., Upchurch G.R., et al. KLF4 regulates abdominal aortic aneurysm morphology and deletion attenuates aneurysm formation. Circulation 2013, 128(11 Suppl. 1):S163-S174.
60. Hoshino Y., Kurabayashi M., Kanda T., Hasegawa A., Sakamoto H., Okamoto E., et al. Regulated expression of the BTEB2 transcription factor in vascular smooth muscle cells: analysis of developmental and pathological expression profiles shows implications as a predictive factor for restenosis. Circulation 2000, 102:2528-2534.
61. Lu Y., Haldar S., Croce K., Wang Y., Sakuma M., Morooka T., et al. Kruppel-like factor 15 regulates smooth muscle response to vascular injury-brief report. Arterioscler Thromb Vasc Biol 2010, 30:1550-1552.
62. Lu Y., Zhang L., Liao X., Sangwung P., Prosdocimo D.A., Zhou G., et al. Kruppel-like factor 15 is critical for vascular inflammation. J Clin Invest 2013, 123:4232-4241.
63. Ruiz-Gomez M., Romani S., Hartmann C., Jackle H., Bate M. Specific muscle identities are regulated by Kruppel during Drosophila embryogenesis. Development 1997, 124:3407-3414.
64. Haldar S.M. Emerging role of kruppel-like factors (KLFs) in skeletal muscle biology. Exp Med 2013, 1-8. Yodosha, Tokyo, Japan.
65. Berkes C.A., Tapscott S.J. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 2005, 16:585-595.
66. Himeda C.L., Ranish J.A., Pearson R.C., Crossley M., Hauschka S.D. KLF3 regulates muscle-specific gene expression and synergizes with serum response factor on KLF binding sites. Mol Cell Biol 2010, 30:3430-3443.
67. Dionyssiou M.G., Salma J., Bevzyuk M., Wales S., Zakharyan L., McDermott J.C. Kruppel-like factor 6 (KLF6) promotes cell proliferation in skeletal myoblasts in response to TGFbeta/Smad3 signaling. Skeletal Muscle 2013, 3:7.
68. Sunadome K., Yamamoto T., Ebisuya M., Kondoh K., Sehara-Fujisawa A., Nishida E. ERK5 regulates muscle cell fusion through Klf transcription factors. Dev Cell 2011, 20:192-205.
69. Egan B., Zierath J.R. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 2013, 17:162-184.
70. Zizola C., Schulze P.C. Metabolic and structural impairment of skeletal muscle in heart failure. Heart Fail Rev 2013, 18:623-630.
71. Rowe G.C., Safdar A., Arany Z. Running forward: new frontiers in endurance exercise biology. Circulation 2014, 129:798-810.
72. Oishi Y., Manabe I., Tobe K., Ohsugi M., Kubota T., Fujiu K., et al. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nature Med 2008, 14:656-666.
73. Gray S., Wang B., Orihuela Y., Hong E.G., Fisch S., Haldar S., et al. Regulation of gluconeogenesis by Kruppel-like factor 15. Cell Metab 2007, 5:305-312.
74. Jeyaraj D., Scheer F.A., Ripperger J.A., Haldar S.M., Lu Y., Prosdocimo D.A., et al. Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab 2012, 15:311-323.
75. Haldar S.M., Jeyaraj D., Anand P., Zhu H., Lu Y., Prosdocimo D.A., et al. Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci U S A 2012, 109:6739-6744.
76. Masuno K., Haldar S.M., Jeyaraj D., Mailloux C.M., Huang X., Panettieri R.A., et al. Expression profiling identifies Klf15 as a glucocorticoid target that regulates airway hyperresponsiveness. Am J Respir Cell Mol Biol 2011, 45:642-649.
77. Sasse S.K., Mailloux C.M., Barczak A.J., Wang Q., Altonsy M.O., Jain M.K., et al. The Glucocorticoid Receptor and KLF15 Regulate Gene Expression Dynamics and Integrate Signals through Feed-Forward Circuitry. Mol Cell Biol 2013, 33:2104-2115.
78. Shimizu N., Yoshikawa N., Ito N., Maruyama T., Suzuki Y., Takeda S., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011, 13:170-182.
79. Bialkowska A.B., Crisp M., Bannister T., He Y., Chowdhury S., Schurer S., et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kruppel-like factor 5 expression by ultrahigh-throughput screening. Mol Cancer Ther 2011, 10:2043-2051.
80. Oishi Y., Manabe I., Imai Y., Hara K., Horikoshi M., Fujiu K., et al. Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension. FASEB J 2010, 24:1780-1788.